Approval · Notice of Compliance 231 · 2003
PROLEV: Notice of Compliance 231
Issued March 14, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 231
- Date
- March 14, 2003
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Admin
- Reason
- Product name change from wellbutrin sr
- Therapeutic class
- Antidepressant
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PROLEV | 02247328 | — |
| PROLEV | 02247329 | — |
| PROLEV | 02247330 | — |
Medicinal ingredients
- BUPROPION HYDROCHLORIDE 50 MG per TAB
- BUPROPION HYDROCHLORIDE 100 MG per TAB
- BUPROPION HYDROCHLORIDE 150 MG per TAB